Literature DB >> 25875542

Preoperative carcinoembryonic antigen and prognosis of colorectal cancer. An independent prognostic factor still reliable.

Giovanni Li Destri1, Antonio Salvatore Rubino, Rosalia Latino, Fabio Giannone, Raffaele Lanteri, Beniamino Scilletta, Antonio Di Cataldo.   

Abstract

To evaluate whether, in a sample of patients radically treated for colorectal carcinoma, the preoperative determination of the carcinoembryonic antigen (p-CEA) may have a prognostic value and constitute an independent risk factor in relation to disease-free survival. The preoperative CEA seems to be related both to the staging of colorectal neoplasia and to the patient's prognosis, although this-to date-has not been conclusively demonstrated and is still a matter of intense debate in the scientific community. This is a retrospective analysis of prospectively collected data. A total of 395 patients were radically treated for colorectal carcinoma. The preoperative CEA was statistically compared with the 2010 American Joint Committee on Cancer (AJCC) staging, the T and N parameters, and grading. All parameters recorded in our database were tested for an association with disease-free survival (DFS). Only factors significantly associated (P < 0.05) with the DFS were used to build multivariate stepwise forward logistic regression models to establish their independent predictors. A statistically significant relationship was found between p-CEA and tumor staging (P < 0.001), T (P < 0.001) and N parameters (P = 0.006). In a multivariate analysis, the independent prognostic factors found were: p-CEA, stages N1 and N2 according to AJCC, and G3 grading (grade). A statistically significant difference (P < 0.001) was evident between the DFS of patients with normal and high p-CEA levels. Preoperative CEA makes a pre-operative selection possible of those patients for whom it is likely to be able to predict a more advanced staging.

Entities:  

Keywords:  Colorectal carcinoma; Disease-free survival; Independent prognostic factor; Preoperative carcinoembryonic antigen

Mesh:

Substances:

Year:  2015        PMID: 25875542      PMCID: PMC4400928          DOI: 10.9738/INTSURG-D-14-00100.1

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  42 in total

1.  More is not always better.

Authors:  Luis A Carriquiry
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

2.  Predictors of distant metastasis and mortality in patients with stage II colorectal cancer.

Authors:  John H Heinzerling; Thomas Anthony; Edward H Livingston; Sergio Huerta
Journal:  Am Surg       Date:  2007-03       Impact factor: 0.688

3.  Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer.

Authors:  Murat Basbug; Zulfu Arikanoglu; Nurullah Bulbuller; Ziya Cetinkaya; Erhan Aygen; Sami Akbulut; Omer Satici
Journal:  Hepatogastroenterology       Date:  2011 Mar-Apr

4.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.

Authors:  H J Wanebo; B Rao; C M Pinsky; R G Hoffman; M Stearns; M K Schwartz; H F Oettgen
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

5.  Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer.

Authors:  Jung Wook Huh; Byung Ryul Oh; Hyeong Rok Kim; Young Jin Kim
Journal:  J Surg Oncol       Date:  2010-04-01       Impact factor: 3.454

6.  Carcinoembryonic antigen (CEA) as a prognostic and monitoring test in clinically complete resection of colorectal carcinoma.

Authors:  M A Herrera; T M Chu; E D Holyoke
Journal:  Ann Surg       Date:  1976-01       Impact factor: 12.969

7.  Can biliary carcinoembryonic antigen identify colorectal cancer patients with occult hepatic metastases?

Authors:  Giovanni Li Destri; Raffaele Lanteri; Marco Santangelo; Benedetto Torrisi; Antonio Di Cataldo; Stefano Puleo
Journal:  World J Surg       Date:  2006-08       Impact factor: 3.352

8.  Utility of serum preoperative carcinoemberyonic antigen in colorectal cancer patients.

Authors:  Saleh El-Awady; R Lithy; M Morshed; W Khafagy; H Abd Monem; Omar Waleed; S Badr; A Fekry; A El Nakeeb; H Ghazy; M El Yamany; T Metwally; Mohamed El-Arman; Mohamed Farid
Journal:  Hepatogastroenterology       Date:  2009 Mar-Apr

Review 9.  Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.

Authors:  M J Duffy; A van Dalen; C Haglund; L Hansson; E Holinski-Feder; R Klapdor; R Lamerz; P Peltomaki; C Sturgeon; O Topolcan
Journal:  Eur J Cancer       Date:  2007-05-18       Impact factor: 9.162

10.  Identification of patients with high-risk stage II colon cancer for adjuvant therapy.

Authors:  Hak-Mien Quah; Joanne F Chou; Mithat Gonen; Jinru Shia; Deborah Schrag; Ron G Landmann; José G Guillem; Philip B Paty; Larissa K Temple; W Douglas Wong; Martin R Weiser
Journal:  Dis Colon Rectum       Date:  2008-03-06       Impact factor: 4.585

View more
  10 in total

1.  Clinical Significance of Early Carcinoembryonic Antigen Change in Patients With Nonmetastatic Colorectal Cancer.

Authors:  Younghoo Jo; Jae-Hoon Lee; Eun-Suk Cho; Hye Sun Lee; Su-Jin Shin; Eun Jung Park; Seung Hyuk Baik; Kang Young Lee; Jeonghyun Kang
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

2.  Characteristics of colorectal cancer diagnosed with screening abdominal ultrasonography.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Rumiko Hasegawa; Kazunori Fugo; Yoshinori Shirai; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Takashi Kishimoto; Naoki Ishige
Journal:  Mol Clin Oncol       Date:  2016-05-11

3.  NMR-based metabolomic techniques identify potential urinary biomarkers for early colorectal cancer detection.

Authors:  Zhening Wang; Yan Lin; Jiahao Liang; Yao Huang; Changchun Ma; Xingmu Liu; Jurong Yang
Journal:  Oncotarget       Date:  2017-11-11

Review 4.  Novel biomarkers for the diagnosis and prognosis of colorectal cancer.

Authors:  Hyung-Hoon Oh; Young-Eun Joo
Journal:  Intest Res       Date:  2019-11-30

Review 5.  Prognostic Factors Involved in the Epithelial-Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis.

Authors:  Eva Parisi; Anabel Sorolla; Robert Montal; Rita González-Resina; Anna Novell; Antonieta Salud; Maria Alba Sorolla
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

6.  Mutated DNA Damage Repair Pathways Are Prognostic and Chemosensitivity Markers for Resected Colorectal Cancer Liver Metastases.

Authors:  Kun Wang; Ming Liu; Hong-Wei Wang; Ke-Min Jin; Xiao-Luan Yan; Quan Bao; Da Xu; Li-Jun Wang; Wei Liu; Yan-Yan Wang; Juan Li; Li-Juan Liu; Xiao-Yu Zhang; Chun-He Yang; Ge Jin; Bao-Cai Xing
Journal:  Front Oncol       Date:  2021-03-31       Impact factor: 6.244

7.  Prognostic Value of Intratumor Metabolic Heterogeneity Parameters on 18F-FDG PET/CT for Patients with Colorectal Cancer.

Authors:  Xin Liu; Kun Xiang; Guang-Yong Geng; Shi-Cun Wang; Ming Ni; Yi-Fan Zhang; Hai-Feng Pan; Wei-Fu Lv
Journal:  Contrast Media Mol Imaging       Date:  2022-01-30       Impact factor: 3.161

8.  Prediction value of 18F-FDG PET/CT intratumor metabolic heterogeneity parameters for recurrence after radical surgery of stage II/III colorectal cancer.

Authors:  Xin Liu; Yi-Fan Zhang; Qin Shi; Yi Yang; Ben-Hu Yao; Shi-Cun Wang; Guang-Yong Geng
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

9.  Characteristics and prognostic factors of colorectal mucinous adenocarcinoma with signet ring cells.

Authors:  Xiangquan Kong; Xueqing Zhang; Yunxia Huang; Lirui Tang; Qingqin Peng; Jinluan Li
Journal:  Cancer Manag Res       Date:  2017-11-02       Impact factor: 3.989

10.  Pre-operative to post-operative serum carcinoembryonic antigen ratio is a prognostic indicator in colorectal cancer.

Authors:  Zhenqiang Sun; Fuqi Wang; Quanbo Zhou; Shuaixi Yang; Xiantao Sun; Guixian Wang; Zhen Li; Zhiyong Zhang; Junmin Song; Jinbo Liu; Weitang Yuan
Journal:  Oncotarget       Date:  2017-05-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.